Our BPC-157 & TB-500 pen is one pre-loaded multi-dose pen holding both molecules together, 32 mg in 3 ml, already in solution. It is the most talked-about repair pairing in the peptide market, and it is also the one where the gap between how confidently it is sold and what the published evidence shows is widest. This section does four things. It separates the two compounds, because they have very different evidence behind them. It says where the evidence for the pair stops. It sets out what arrives and what the certificate for your batch shows. And it covers the cold chain, the arrival check and returns. Background on the two molecules is at what is BPC-157 & TB-500?.
BPC-157: a large preclinical literature from one group
BPC-157 is a synthetic pentadecapeptide, fifteen amino acids long, derived from a sequence identified in human gastric juice. It was first described by Sikiric and colleagues at the University of Zagreb in the early 1990s, and the preclinical literature since is genuinely large, covering tendon, ligament, muscle, bone and gastrointestinal models, with reported effects on angiogenesis, collagen synthesis, fibroblast activity and inflammatory signalling. A 2025 systematic review written from an orthopaedic sports-medicine perspective found 36 eligible studies, 35 of them preclinical and one clinical. Vasireddi N et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J 2025. PMID 40756949; Józwiak M et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide. Pharmaceuticals 2025. PMID 40005999
There is a structural feature of that literature that product pages rarely mention. A 2026 development review notes that more than 80% of published BPC-157 studies, by author affiliation, come from a single group at the University of Zagreb, and that independent replication across geographically and institutionally separate laboratories is largely absent. Mateescu DM et al. BPC-157 as an Investigational Peptide Therapeutic. Pharmaceutics 2026. PMID 42198317 That is not an accusation of anything; it is a description of the evidence base, and it cuts both ways. A favourable effect that only one group’s models produce is weakly established, and so is the absence of an adverse effect that only one group’s models have looked for.
What BPC-157’s human exposure covers
Despite three decades of work there is no approved formulation, no validated dosing regimen and no completed Phase II clinical trial. The same 2026 review puts the available clinical data at fewer than 30 subjects across three uncontrolled pilot studies, none of which used a standardised pharmaceutical preparation, and traces the early-phase work to Pliva in Croatia, which ran it for inflammatory bowel disease under codes including PL14736 and produced limited tolerability data. Mateescu DM et al. BPC-157 as an Investigational Peptide Therapeutic. Pharmaceutics 2026. PMID 42198317 A tolerability finding in one gut indication is not evidence of long-term safety, of safety by another route, or of effectiveness for tendon and ligament repair. The systematic review above found no clinical safety data at all, and noted that the compound is metabolised in the liver with a half-life of less than 30 minutes. Vasireddi N et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J 2025. PMID 40756949
TB-500 is a fragment; the trials were of the whole protein
Thymosin beta-4 is a naturally occurring 43-amino-acid protein with a well-described role in actin regulation and cell migration. TB-500 is a synthetic fragment of that protein, not the full-length molecule. That matters more than it sounds, because the human trials described below were run on full-length thymosin beta-4, and data generated on the whole protein does not automatically describe a fragment of it: different molecule, different pharmacokinetics, potentially different activity. How the two halves of this pen differ from each other is set out at BPC-157 vs TB-500.
Thymosin beta-4’s human trials studied a different route
Unlike BPC-157, thymosin beta-4 has been through registered, placebo-controlled human trials. A Phase II study in moderate-to-severe dry eye randomised 72 subjects to 0.1% thymosin beta-4 ophthalmic solution or placebo for 28 days; neither primary endpoint showed a significant difference, several secondary endpoints did, and no adverse events were reported. Sosne G et al. Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial. Clin Ophthalmol 2015. PMID 26056426; ClinicalTrials.gov NCT01387347 A second Phase II, also with 72 patients, tested three concentrations of a thymosin beta-4 gel against placebo on venous stasis ulcers. ClinicalTrials.gov NCT00832091
Read the route carefully. Those are eye drops and a wound gel, studied for eye-surface and wound-healing indications. They are not trials of injection for tendon, ligament or muscle repair, which is what almost everyone who looks at this pen has in mind. The human record exists, for a different route, a different formulation, a different indication and, as above, a different molecule.
Why both are in one pen, and where the evidence for the pair stops
The rationale for pairing them, and for the repair peptides class as a whole, is mechanistic: BPC-157 has been studied mostly in localised repair models, thymosin beta-4 in cell migration and wound response, so the two are thought to act on different parts of tissue repair. Putting both in one cartridge means one pen instead of two. No published human trial has given the two together and measured the result, so the combination has no direct evidence of its own. What it has is the separate evidence above, and that evidence is preclinical for one molecule and topical for the other.
Two things about the format are simply facts. The pen holds both molecules at a fixed ratio, 32 mg in 3 ml between them. We do not sell either compound on its own, and the ratio in the cartridge cannot be changed. And the pen’s advantages over other formats are format and verification, not outcomes: nothing to reconstitute, nothing to draw up from a vial, and a certificate that belongs to the batch in your hand. How pens and vials compare in practice is at pen vs vial.
| Molecule | Human evidence | Trials of injection for repair |
|---|
| BPC-157 | Fewer than 30 subjects, uncontrolled pilot studies | None completed |
| Thymosin beta-4 | Phase II eye drops and wound gel | None |
| The pair together | No published trial | None |
What arrives, and what the certificate shows
The parcel holds the pen, eight standard threaded pen needles, a printed guide and a verification sticker, in insulated packaging with a cooling element and a temperature indicator, inside discreet outer packaging.
An independent laboratory tests every batch for identity by mass spectrometry, purity by HPLC and sterility, and the certificate is published per batch. The certificate for your batch shows the HPLC purity figure and the concentration of the cartridge, as mg/ml and as total mg per 3 ml. You reach it by scanning the QR code on the pen, which resolves to the certificate for that batch, or from the certificate index; it is a plain PDF and needs no account. We do not name the laboratory. What each line on it means, and how to compare it with the pen in front of you, is at how to read a certificate of analysis.
Cold chain, arrival check and returns
The pen travels at 2–8 °C from our Czech dispatch point to your refrigerator, in the insulated packaging with the cooling element and temperature indicator described above. Orders placed before 12:00 on a business day dispatch the same day. Delivery takes 3–5 business days across the EU, tracked door to door, with the tracking link by email and WhatsApp updates if you opt in. Because dispatch is inside the EU, EU deliveries carry no customs charges and no import paperwork. Shipping cost is shown at checkout before you pay. How the chain is kept, and what the indicator is telling you, is at cold-chain shipping.
When the parcel arrives, look at the indicator first. If it shows a breach, or if a pen arrives damaged, broken or not working, send us photos or a short video of the fault and we replace the pen free of charge. Unopened, unused pens in their original sealed packaging can be returned within 30 days of delivery for a full refund to the original payment method, processed within 5 business days of approval. Opened or used pens cannot be returned. The full terms are at returns.
Status, and where this pen sits in the range
Neither BPC-157 nor thymosin beta-4 is an authorised medicine in the EU, and neither appears among the European Medicines Agency’s centrally authorised products. Why that is, and what it does and does not tell you about a compound, is set out at why these compounds are not EMA-authorised.
Within our range this pen is the recovery product. If the goal you are looking at also takes in skin and collagen, the Elite Repair Stack puts it next to our GHK-CU 50 pen, whose human data is mostly topical and is set out on its own page. What we can evidence about this pen is what is in it: identity, purity, sterility and batch traceability, and we publish the document behind that. What we will not do is present a preclinical literature dominated by one group, and a set of human trials by a different route on a different molecule, as though they establish that this pen repairs injuries in people. They do not, and pages that imply otherwise are the reason this one reads the way it does.
